Incyte Corporation (INCY)vsJohnson & Johnson (JNJ)
INCY
Incyte Corporation
$121.47
-1.47%
HEALTHCARE · Cap: $25.22B
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1583% more annual revenue ($97.93B vs $5.82B). INCY leads profitability with a 27.7% profit margin vs 21.5%. JNJ appears more attractively valued with a PEG of 2.79. INCY earns a higher WallStSmart Score of 76/100 (B+).
INCY
Strong Buy76
out of 100
Grade: B+
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.0%
Fair Value
$619.23
Current Price
$121.47
$497.76 discount
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 41.9%
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Keeps 28 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 27.7% and operating margin at 41.9%. Revenue growth of 37.7% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : INCY
The primary concerns for INCY are PEG Ratio.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
INCY profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.77 — expect wider price swings.
INCY is growing revenue faster at 37.7% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
INCY scores higher overall (76/100 vs 59/100), backed by strong 27.7% margins and 37.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?